A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...
Epithelial ovarian cancer (EOC) is an aggressive malignancy with limited therapeutic options. Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown remarkable efficacy, especially in BRCA-mutant ...
A new study introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients.
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...
Please provide your email address to receive an email when new articles are posted on . Saruparib at 60 mg/day demonstrated deep, durable responses with a high response rate and tumor reduction in ...
In patients with advanced epithelial ovarian cancer, first-line maintenance therapy with PARP inhibitors was associated with a progression-free survival benefit compared with standard chemotherapy ...
The University of Texas MD Anderson Cancer Center’s Timothy Yap, M.D., doesn’t know why AstraZeneca’s PARP inhibitor saruparib seems to be spurring responses in patients who have previously not had ...
Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...
SAN DIEGO -- Saruparib, an investigational selective PARP1 inhibitor, showed promising activity in patients with certain homologous recombination repair (HRR)-deficient breast cancers, while limiting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback